Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · MUSTANG BIO, INC. (MBIO)

Mustang Bio stockholders approve seven directors, KPMG and two plan share increases

Neutral Impact 2 of 5 shareholder Written later

At its December 22, 2025 annual meeting, Mustang Bio stockholders approved all four proposals, including electing seven directors, ratifying KPMG LLP as auditor, and increasing shares under its employee stock purchase plan and 2016 Incentive Plan. Separately, the company disclosed a December 17, 2025 agreement to terminate its CD20 license with Fred Hutch Cancer Center, under which the company will pay $730,000 to extinguish about $1.4 million in payables owed to Fred Hutch.

Key points

  • The 2016 Incentive Plan amendment adds 2,500,000 shares, and the 2019 ESPP amendment adds 250,000 shares.
  • The Incentive Plan amendment received 7,664,161 votes for, 198,991 against and 4,278 abstentions.
  • Each of the seven director nominees received at least 7,712,919 votes for.
  • Under the termination agreement, Fred Hutch would pay at least 10% of consideration from any third-party CD20 license granted within three years.

The filing

CompanyMUSTANG BIO, INC. (MBIO)
Form8-K, current report
Filed with the SECDec 23, 2025, 4:05 PM ET
Accession number0001104659-25-124189

Items reported: 5.07 Shareholder Vote Results8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 23, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.